Psoriatic Arthritis with Peripheral Monoarthritis or Oligoarthritis (≤4 Swollen Joints) and No Poor Prognostic Factors
This first-line protocol addresses psoriatic arthritis presenting as peripheral monoarthritis or oligoarthritis — four or fewer swollen joints — in patients without adverse prognostic markers.
Clinical Scenario
The patient has peripheral monoarthritis or oligoarthritis with ≤4 swollen joints and none of the following poor prognostic factors: structural damage, elevated acute phase reactants, dactylitis, or nail involvement. Oligoarticular disease without these markers carries a more favourable long-term prognosis, and there is correspondingly less urgency to escalate treatment.
Treatment Overview
Initial management involves anti-inflammatory medication to relieve musculoskeletal symptoms, with local adjunctive injection therapy considered where appropriate. Symptomatic treatment in this setting is intended to be short term — generally around four weeks — before further management decisions are reviewed.
Treatment Goal
Relief of musculoskeletal signs and symptoms within 4 weeks.
References
DOI: 10.1136/ard-2024-225531
- Patients with oligoarticular disease and lack of poor prognostic factors should also receive a csDMARD, but there is less urgency for these patients given the more favourable long-term prognosis.
- The latter may receive csDMARDs after a longer delay, and potentially a period of symptomatic treatment alone.
- Non-steroidal anti-inflammatory drugs may be used to relieve musculoskeletal signs and symptoms; local injections of glucocorticoids may be considered as adjunctive therapy.
- The use of symptomatic treatments alone should usually be short term, for example, limited to 4 weeks or so.